DV
Dividend Vision

NBTX — Nanobiotix

Nanobiotix (NBTX)

Total return is 125.6% over the past 5.7 years, 3.6 points behind SPY at 129.2%. Its deepest 1-year drawdown was 50.2%.

Nanobiotix is a clinical-stage biotechnology company focused on developing cancer treatments, with its lead candidate NBTXR3—a nanoparticle therapy—in development for soft tissue sarcoma and multiple other cancer types across markets including China, South Korea, Singapore, and Thailand. The company does not currently distribute dividends. Nanobiotix appeals to investors seeking exposure to early-stage cancer research and biotechnology development rather than current income.

NBTX key facts

Asset type
Stock
Asset class
Equity
Inception date
12/11/2020
Last close
$38.31
Market cap
$1,814,576,000
Average volume
238371.0
Beta
0.56
Payout ratio
0.0
Forward P/E
102.0408
EPS
$-0.54